Bicara CEO exercises options, sells 10,000 shares
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Bicara Therapeutics Inc. director and Chief Executive Officer Claire Mazumdar exercised options to acquire 10,000 shares of common stock at $3.7898 per share, then sold 10,000 shares in open-market transactions on July 10, 2026, pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026, and continues to hold shares directly.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($246K approx. pre-tax spread)
Exercise and Sale
4 txns
Insider
Mazumdar Claire
Role
Chief Executive Officer
Sold
10,000 shs ($284K)
Approx. gross sale proceeds
$284K
Approx. exercise cost
$38K
Approx. pre-tax spread
$246K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 10,000 | $3.7898 | $38K |
| Sale | Common Stock F1, F2 | 9,972 | $28.4163 | $283K |
| Sale | Common Stock F1 | 28 | $29.68 | $831.04 |
Holdings After Transaction:
Stock Option (Right to Buy) — 120,546 contracts (Direct);
Common Stock — 362,152 shares (Direct)
Footnotes (3)
- F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026.
- F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.13 to $28.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
- F3. The shares underlying this option vest in sixteen equal quarterly installments following April 5, 2023, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Shares sold: 10,000 shares
Sale price (small lot): $29.68 per share
Weighted-average sale price: $28.4163 per share
+5 more
8 metrics
Shares sold
10,000 shares
Total BCAX common shares sold in open-market transactions on 2026-07-10
Sale price (small lot)
$29.68 per share
Price for sale of 28 BCAX common shares on 2026-07-10
Weighted-average sale price
$28.4163 per share
Weighted-average price for sale of 9,972 BCAX shares on 2026-07-10; trades ranged $28.13–$28.81
Options exercised
10,000 shares
Common shares acquired via option exercise on 2026-07-10
Option exercise price
$3.7898 per share
Conversion price for Stock Option (Right to Buy) underlying 10,000 BCAX shares
Common shares held after sale
362,152 shares
Direct BCAX common stock holdings reported following one of the 2026-07-10 sales
Options remaining
120,546 shares
Option shares remaining under the reported Stock Option (Right to Buy) after the 10,000-share exercise
Option expiration
April 5, 2033
Expiration date of the Stock Option (Right to Buy) related to the exercised shares
Key Terms
Rule 10b5-1 trading plan, weighted average price, Stock Option (Right to Buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 31, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"The shares underlying this option vest in sixteen equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BCAX CEO Claire Mazumdar report on July 10, 2026?
Claire Mazumdar reported exercising options for 10,000 Bicara Therapeutics (BCAX) shares at $3.7898 and selling 10,000 common shares in open-market transactions on July 10, 2026, while continuing to hold a direct equity position.
What stock options did the BCAX CEO exercise in the reported Form 4?
The CEO exercised a Stock Option (Right to Buy) for 10,000 BCAX shares at a conversion price of $3.7898 per share. Following this exercise, 120,546 option shares associated with this option grant remained outstanding, expiring on April 5, 2033.
AI-generated analysis. How Rhea-AI works. Not financial advice.
